Your session is about to expire
← Back to Search
Tazemetostat for Solid Tumors
This trial is testing whether or not a drug that targets EZH2 will be effective in treating patients with B-cell non-Hodgkin's lymphoma, epithelioid sarcoma, and other solid tumors.
- ARID1A Mutation
- Solid Tumors
Inclusion CriteriaYou will be eligible if you check “Yes” for the criteria below
Study ObjectivesOutcome measures can provide a clearer picture of what you can expect from a treatment.
Side effects dataFrom 2021 Phase 2 trial • 20 Patients • NCT03456726
Awards & Highlights
Find a Location
Who is running the clinical trial?
- Group 1: Tazemetostat
Frequently Asked Questions
Have there been any prior investigations regarding Tazemetostat?
"Presently, 20 different trials researching Tazemetostat are ongoing. Two of those studies have reached Phase 3 and the majority of them are based in Marshfield, Wisconsin. Nevertheless, 1,302 medical centres across the globe are running clinical trials examining this treatment."
Is this research initiative still open to enrollees?
"Affirmative. The clinical trial portal, clinicaltrials.gov, posts that this experiment is actively enrolling participants since the first post of January 6th 2022 and was last updated on February 15th 2022. Currently recruiting 40 patients from a single location."
Is Tazemetostat a reliable treatment option for individuals?
"Upon investigation, our team at Power rated Tazemetostat's safety as a 2 due to the lack of clinical data in support of its efficacy. This is expected for Phase 2 trials."
Does this research endeavor represent a pioneering effort?
"At present, 20 clinical trials are ongoing for Tazemetostat in 533 cities spread across 21 countries. The first drug study was initiated by Epizyme Inc. back in 2015 and comprised of 250 participants; since then the company has conducted 8 further investigations with Phase 2 approval status achieved."
How many participants can this clinical trial accommodate?
"Affirmative. According to information featured on clinicaltrials.gov, this clinical trial is presently recruiting patients and was initially put up for public view on the 6th of January 2022 before being updated a month later in February 15th 2021. 40 individuals are required to come forward from 1 single site."
Share this study with friends